Brain cancer trial adds spinal-fluid chemo to standard therapy

NCT ID NCT07193654

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a chemotherapy drug (thiotepa) directly into the spinal fluid can help people with glioblastoma that has invaded the brain's ventricles or lining. Participants will first have surgery to remove as much tumor as possible, then receive radiation, oral temozolomide, and the spinal-fluid injections. The goal is to see if this combination improves how long people live without the cancer growing. The trial is currently recruiting 38 adults aged 18–75.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: thiotepa (given into the spinal fluid) and temozolomide (oral chemotherapy)
What this could lead to: If it works, this could offer a new treatment option for people with glioblastoma that has spread to the brain's lining or fluid spaces, potentially improving survival.
What could go wrong: This is a small, early-phase study with only 38 participants and no comparison group. The added thiotepa may cause serious side effects like infection or nerve damage, and it is not yet proven to help.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma Meningeal Carcinomatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA (GBM)

Contacts and locations

Locations

2nd Affiliated Hospital, School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.